Hers

Provider Profile Name: Hers (Weight Loss by Hers)
Parent Company: Hims & Hers Health, Inc. (NYSE: HIMS)
Website: forhers.com
Founded: 2018
Provider Type: Telehealth — Virtual Only, Women-Focused Platform
Headquarters: San Francisco, CA

Operating Details

• Fully virtual — online assessment, licensed provider review, home delivery
• No monthly membership fee; FSA/HSA eligible; does not accept insurance
• Not available in all 50 states — verify availability before beginning intake
• App included with active subscription at no additional cost, covering nutrition, movement, and sleep habit protocols
• No named medical director publicly disclosed

Approach Hers (forhers.com) is the women’s brand of Hims & Hers Health Inc., a publicly traded telehealth company on the New York Stock Exchange. They launched in 2018 as a women-focused counterpart to Hims and expanded from birth control, skincare, and hair loss into weight management. The platform is designed around accessibility and price transparency, offering both low-cost compounded and brand-name GLP-1 options from one platform — with all plans prepaid upfront rather than billed month-to-month.

About the Company

As a publicly traded company, Hers offers accountability through quarterly financial reporting and a board of directors that smaller telehealth startups cannot match. That institutional structure does not protect against regulatory action, however.

FDA Warning Letter — September 9, 2025

The FDA issued a warning letter to Hims & Hers Health, Inc. dba Hers dated September 9, 2025, regarding certain compounded semaglutide marketing claims. The warning reflects the same category of violation seen elsewhere in this review series — marketing language that implied FDA approval or equivalence for compounded products that have not been through FDA review. The platform updated its marketing disclosures following the letter, and the Hers website now includes prominent disclaimers distinguishing compounded medications from FDA-approved branded products.

GLP-1 Weight Loss

• Lose pounds of fat every week
• Money Back Guarantee
• No membership or hidden fees! Everything you need is included
• Start for just $179, no insurance required + free shipping

GLP-1 for Just $179

100k MembersHSA/FSA ApprovedFrom $179

The FDA declared the semaglutide shortage resolved in February 2025, which affects the regulatory framework under which compounded semaglutide products may be prepared and distributed — a landscape that continues to evolve.

GLP-1 Offerings and Weight Loss Services

Hers offers one of the broadest medication menus of any platform in this review series:

Compounded Medications:

• Compounded Semaglutide (injectable) — once-weekly injection; same active ingredient as Ozempic and Wegovy but not FDA-approved

Brand-Name Options (for eligible patients):

• Wegovy (semaglutide, FDA-approved for weight loss), Ozempic (semaglutide, off-label for weight loss), Zepbound and Mounjaro (tirzepatide), generic liraglutide (daily injection)

Oral Medication Kits (non-injectable):

• Personalized oral combinations of naltrexone + bupropion, with options to add metformin or topiramate — from $69/month as a 10-month prepaid plan

App and Support Features:

• Access to the Hers app including dynamic protocols to help improve nutrition, movement, and sleep-based habits for sustained weight loss
• Prescription anti-nausea medication (ondansetron) included for eligible patients on GLP-1 injections at no extra cost
• 24/7 provider messaging access included

Hers reports that on average customers lost 11.1 lbs with compounded GLP-1 injections and 7.9 lbs with oral medication kits in the first two months of treatment alongside a reduced-calorie diet and exercise. These are self-reported, platform-derived figures rather than independent clinical trial data.

Pricing — and What Reviewers Say

Costs range from $69 to $1,899 per month depending on medication — with no monthly membership fee on top of that price. All plans are prepaid:

• Oral non-GLP-1 medication kits: from $69/month — available only as a 10-month prepaid plan
• Compounded semaglutide (injectable): from $199/month on a 6-month plan, paid upfront in full; 2- and 4-month plans also available
• Brand-name injectables: priced at retail or near-retail; Wegovy, Ozempic, Zepbound, and Mounjaro available, with costs reaching up to $1,899/month for certain brand-name plans
• Lab work: $75–$100 if required; not included in the plan price

The prepaid model means patients commit upfront — a structure that benefits budget planning but limits flexibility if a medication doesn’t work as expected.

What reviewers say about pricing: Reviewers consistently cite competitive pricing as Hers’ primary strength, with the oral medication kit entry point and compounded semaglutide starting rate drawing patients who previously found GLP-1 access out of reach. However, the prepaid structure draws the most consistent friction in reviews — patients who find the medication ineffective or experience side effects report difficulty obtaining refunds given the upfront payment model, and the lack of flexibility mid-plan is a recurring complaint. The absence of a separate membership fee is genuinely appreciated, but patients should read plan terms carefully before paying multiple months upfront.

Reviews from Trustpilot and Google

Hers has over 6,200 Trustpilot reviews at 3.4/5 at time of writing — a meaningful volume but a lower aggregate score than most platforms in this review series.

What patients praise:

• Straightforward onboarding, competitive pricing, and a polished platform experience
• The broad medication menu, including oral non-injectable options for needle-averse patients
• App access with habit trackers and lifestyle tools included at no extra cost

Common complaints:

• The 3.4/5 Trustpilot rating reflects operational issues with customer service and fulfillment that can make the experience frustrating at scale
• The prepaid plan structure means patients are locked into upfront payment before confirming the medication works for them
• Limited provider access and infrequent follow-ups compared to more clinically supervised platforms

Compounding Pharmacies Used

Specific compounding pharmacy partners are not publicly disclosed on the Hers website. Compounded semaglutide is dispensed through licensed US pharmacy partners under prescription. Patients should ask which pharmacy will fulfill their order and whether it holds 503A or 503B designation before beginning treatment.

Note: Hers received an FDA warning letter on September 9, 2025 for marketing claims on compounded semaglutide — the platform updated its disclosures in response. As a publicly traded company, Hers carries institutional accountability that smaller platforms lack, but its 3.4/5 Trustpilot score across 6,200+ reviews suggests meaningful operational inconsistency at scale. All plans are prepaid upfront — patients should confirm medication eligibility and comfort with the plan structure before committing. Compounded medications are not FDA-approved. Always consult a licensed medical provider before beginning any GLP-1 program.